[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"eclampsia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:eclampsia":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,52,75,100,127,153],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":38,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100537733","phase-4-treatment-with-aspirin-after-preeclampsia-tap-trial-100537733",false,"NCT06281665","Treatment With Aspirin After Preeclampsia: TAP Trial","TAP","Inclusion Criteria:\n\n* Postpartum individuals ≥18 years old\n* Preeclampsia diagnosis\n\nExclusion Criteria:\n\n* Fetal anomaly\n* Multiple gestation\n* Pre-pregnancy hypertension\n* Allergy or contraindication to low-dose aspirin\n* Pre-pregnancy diabetes","FEMALE","18 Years","55 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and\u002For microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.",[27,28,29,30,31,32,33,34,35,36,37],"Hypertensive Disorder of Pregnancy","Pre-Eclampsia","Hypertension","Eclampsia","Gestational Hypertension","Cardiovascular Diseases","Toxemia","Pregnancy Complications","Vascular Diseases","Hypertension, Pregnancy Induced","Hypertension;Pre-Eclamptic",[29],"RECRUITING","2026-06-03",{"date":42,"type":43},"2026-06-04","ACTUAL",{"date":45,"type":43},"2024-05-29",{"date":47,"type":21},"2027-09-01",{"name":49,"class":50},"Malamo Countouris","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":51},"100253506","piers-and-bis-sfitpigf-adrenomedullin-100253506","NCT02578810","PIERS and BIS, sFIT:PIGF, Adrenomedullin","Sensitivity and Specificity of Bispectral Index (BIS) EEG Parameter, sFIT (Soluble FMS Tyrosine Kinase): PIGF (Placental Growth Factor) Ratio, Adrenomedullin for Grading Preeclampsia Integrated Estimate Risk Score (PIERS)","BIS2","Inclusion Criteria\n\n1. Pregnancy at any stage (3 trimesters)\n2. Eclampsia (Frank eclampsia) will be the crux of the study\n3. Pre-eclampsia that is suspected will end up with Frank Eclampsia\n\nExclusion criteria:\n\n1. Any neurological conditions that can alter the electroencephalography like epilepsy\n2. Any medical conditions that can alter the electroencephalography like hypoglycemia","50 Years",{"count":62,"type":21},48,"OBSERVATIONAL","Pre-eclampsia, more than being proteinuric gestational hypertension alone, is a state of exaggerated systemic inflammation and remains a leading direct cause of maternal morbidity and mortality worldwide.1 Standardization of antenatal and postnatal assessment and surveillance of pre-eclampsia with protocols that recognize the systemic inflammatory model of preeclampsia have been associated with reduced maternal morbidity.",[30],"2026-04-22",{"date":68,"type":43},"2026-04-23",{"date":70,"type":4},"2016-10",{"date":72,"type":21},"2030-12",{"name":74,"class":50},"Suez Canal University",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100632198","phase-4-vitamin-d-supplementation-among-pregnant-women-in-uganda-for-the-prevention-of-hypertensive-disorders-in-pregnancy-and-other-adverse-maternal-and-foetal-outcomes-100632198","NCT07510568","Vitamin D Supplementation Among Pregnant Women in Uganda for the Prevention of Hypertensive Disorders in Pregnancy, and Other Adverse Maternal and Foetal Outcomes","Vitamin D Supplementation Among Pregnant Women in Uganda and for the Prevention of Adverse Obstetric Outcomes: a Randomized Controlled Trial","MAMA","Inclusion Criteria:\n\nWomen of age ≥ 18 years, who attend ANC services at St. Mary's Hospital Lacor, satisfying the following criteria:\n\n* with a viable intrauterine pregnancy,\n* at gestational age at recruitment between 13 weeks 0 days and 27 weeks 6 days, and\n* who consented to participate in the study.\n\nExclusion Criteria:\n\n* women already on Vitamin D treatment prescribed by a physician.",{"count":84,"type":21},1980,[24],"The goal of this randomised controlled trial is to investigate if vitamin D supplementation among pregnant women in Uganda prevents adverse maternal and foetal outcomes, with special emphasis on preeclampsia.\n\nThe main question it aims to answer is if Vitamin D supplementation, administered as oral vitamin D₃ at a dose of 2,000 IU once daily, from the time of recruitment to the time of delivery, reduces the incidence of preeclampsia, eclampsia and HELLP syndrome in pregnant women attending ANC at St. Mary's Hospital, Lacor, such incidence being monitored up to six (6) weeks after delivery.\n\nResearchers will compare the effect of oral 2.000 IU vitamin D daily (intervention group) vs. oral placebo daily (control group) on the prevalence of adverse maternal and foetal outcomes.",[88,30,89],"Preeclampsia","HELLP Syndrome","NOT_YET_RECRUITING","2026-04-01",{"date":93,"type":43},"2026-04-03",{"date":95,"type":21},"2026-06-01",{"date":97,"type":21},"2027-12-31",{"name":99,"class":50},"St Mary's Hospital, Lacor",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":110,"studyType":63,"phases":4,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":51},"100604578","pilot-project-renal-and-cardiovascular-tertiary-prevention-in-preeclampsia-100604578","NCT07151339","Pilot Project Renal and Cardiovascular Tertiary Prevention in Preeclampsia","Pilotprojekt Renale Und kardiovaskuläre Tertiärprävention Nach Präeklampsie","EagleEye3P","Inclusion Criteria:\n\n* older than 18 yrs\n* diagnosed preeclampsia, HELLP syndrome or kidney disease durig pregnancy\n\nExclusion Criteria:\n\n* unable for informed consent",{"count":109,"type":21},100,"12 Months","Tertiary prevention program for women with preeclampsia, HELLP syndrome, kidney disease and pregnancy or associated conditions, including founding of a biobank. (Observational study since no interference with regular path of treatment suggested in national and international guidelines)",[88,89,30,113],"Kidney Disease",[115,116,117],"cardiovascular prevention","preeclampsia","pregnancy","2025-08-28",{"date":120,"type":43},"2025-09-03",{"date":122,"type":43},"2024-11-01",{"date":124,"type":21},"2030-11",{"name":126,"class":50},"University Hospital Schleswig-Holstein",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":51},"100491356","point-of-care-ultrasound-abnormalities-in-eclampsia-100491356","NCT05678062","Point-of-care Ultrasound Abnormalities in Eclampsia","Point-of-care Ultrasound Abnormalities in Eclampsia - Prevalence and Association Between Pulmonary Interstitial Syndrome and Cardiac Dysfunction, Brain Natriuretic Peptide, and Serum Albumin","Inclusion Criteria:\n\n* Diagnosis of preeclampsia following ACOG definition with new onset of tonic-clonic seizures.\n\nExclusion Criteria:\n\n* Chronic pulmonary disease\n* Collagen disorders\n* HIV infection if CD4 count \\\u003C200 cells\u002F mm3\n* Chronic renal or hepatic disease\n* Urinary tract infection\n* Sepsis\n* Body mass index (BMI) \\> 50 kg\u002Fm2\n* History of seizure disorder\n* Intracranial haemorrhage\n* History of benign or malignant intracranial neoplasia",{"count":135,"type":21},70,[137],"NA","Preeclampsia (PE) and eclampsia remain leading causes of maternal morbidity and mortality, in both high-, low-and-middle-income countries. Preeclampsia is a complex, multisystem disease which, in its severe form, affects the cardiovascular, renal, hepatic, neurological and haematological systems. Given the complexity of the disease, anaesthesia management for caesarean section in these patients remains challenging. Preeclampsia may be complicated by the development of eclampsia, which involves one or more seizures, which complicates anaesthesia and obstetrics management, and requires. urgent admission and delivery. Recent studies have demonstrated novel markers of severity of PE, including point-of-care ultrasound (POCUS), acid-base changes secondary to low serum albumin, and brain natriuretic peptide (BNP). POCUS is playing an increasing role in perioperative diagnosis, and newer, less expensive devices are continuously being developed. These will in all likelihood play an important role in South Africa in the near future. In a recent trial performed at the University of Cape Town, a comprehensive acid-base analysis in women with PE with severe features demonstrated significant abnormalities in independent acid-base determinants. In addition, strong indications were found that changes in acid-base status following a decrease in serum albumin are more pronounced in early onset PE and may be associated with urgent delivery. In other clinical arenas in critically ill patients, low serum albumin is associated with increased lung water, increased intracranial pressure, and outcome. The research team hypothesised that similar associations might be found in women with late onset preeclampsia with severe features. Using POCUS, it was found that there was no association between serum albumin level and PIS or optic nerve sheath diameter (ONSD). PIS was however associated with cardiac dysfunction, as was BNP.",[30],[141,142,143],"Pulmonary interstitial syndrome","Cardiac dysfunction","Brain natriuretic peptide","2024-07-15",{"date":146,"type":43},"2024-07-17",{"date":148,"type":43},"2022-11-21",{"date":150,"type":21},"2024-12",{"name":152,"class":50},"University of Cape Town",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":160,"sex":161,"minAge":162,"maxAge":4,"enrollmentInfo":163,"targetDuration":165,"studyType":63,"phases":4,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":51},"100545129","the-preeclampsia-registry-100545129","NCT06377878","The Preeclampsia Registry","TPR","Inclusion Criteria:\n\n* Women who were medically diagnosed with preeclampsia or a related hypertensive disorder of pregnancy (HDP) such as eclampsia or HELLP syndrome.\n* Female or Male relatives of affected women\n* Women who have never had preeclampsia or hypertensive disorders of pregnancy, but who would like to serve as \"controls\" in research studies of preeclampsia.\n* An authorized representative may complete the questionnaire and provide consent for a woman who had preeclampsia, but has died or is disabled as a result.\n\nExclusion Criteria:\n\n* Those unable to provide consent\n* Prisoners\n* Individuals unable to speak English",true,"ALL","13 Years",{"count":164,"type":21},20000,"20 Years","The purpose of The Preeclampsia Registry is to collect and store medical and other information from women who have been medically diagnosed with preeclampsia or a related hypertensive (high blood pressure) disorder of pregnancy such as eclampsia or HELLP syndrome, their family members, and women who have not had preeclampsia to serve as controls. Information from participants will be used for medical research to try to understand why preeclampsia occurs, how to predict it better, and to develop experimental clinical trials of new treatments. The Registry will consist of a web-based survey and mechanism for collecting and reviewing medical records. This data will be utilized for immediate investigator-driven cross-sectional research projects (after proposal review by the Registry's scientific advisory board and as directed by the PI). Participants may also choose to be contacted regarding possible participation in future studies, about providing a biospecimen, as well as investigator-driven clinical trials. The Registry is anticipated to exist long-term and to serve as a foundation of participants from which to draw for studies of preeclampsia, anticipated to evolve as our scientific understanding of preeclampsia evolves.",[88,30,89,33,27],[88,30,169,89,33,27,170,171,172,173,174,175,29],"HELLP","Registry","Pregnancy Complication","Pregnancy","Maternal Death","Premature","High Blood Pressure","2024-04-17",{"date":178,"type":43},"2024-04-22",{"date":180,"type":43},"2013-09-01",{"date":182,"type":21},"2040-05",{"name":184,"class":50},"Preeclampsia Foundation"]